Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients

How to Cite

OrthoEvidence. Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients. ACE Report. 2013;2(8):33. Available from: https://myorthoevidene.com/AceReport/Report/4488

Study Type:Therapy

OE Level Evidence:2

Journal Level of Evidence:N/A

Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole

Cancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10

Contributing Authors: AM Brufsky WG Harker JT Beck L Bosserman C Vogel C Seidler L Jin G Warsi E Argonza-Aviles J Hohneker SG Ericson EA Perez

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

OE EXCLUSIVE

Dr. Adam M. Brufsky discusses the use of adjuvant zoledronic acid to maintain bone mass in postmenopausal breast cancer patients.

Synopsis

602 postmenopausal women receiving adjuvant letrozole were randomized either to upfront zoledronic acid or delayed-start zoledronic acid to determine which method minimizes bone-loss. At 5 years follow-up, upfront zoledronic acid was better at maintaining bone mineral density (BMD) in postmenopausal breast cancer patients than the delayed start technique.